The MCV2 immunization coverage in the US was at approximately 96% in 2023. Forecasted data from 2024 to 2028 shows an increasing trend, rising from 97% in 2024 to 99% by 2027 and maintaining 99% in 2028. This translates to a year-on-year increase of about 1% to 2% initially, stabilizing at a high coverage rate towards the end of the forecast period. The compound annual growth rate (CAGR) reflects a steady and slight annual increase over the five years.
Future trends to watch include monitoring any factors that could influence vaccine hesitancy or accessibility, as well as potential policy changes. Efforts to sustain or further improve coverage will be crucial, particularly in light of any emerging public health challenges.
